Navigation Links
CSA Medical Appoints Wendelin Maners VP of Emerging Therapies
Date:9/12/2011

BALTIMORE, Sept. 12, 2011 /PRNewswire/ -- CSA Medical, Inc. (www.CSAmedical.com), the leading developer of novel Spray Cryotherapy devices that flash freeze and treat diseased tissue inside the body, today announced the appointment of Wendelin Maners to the newly created position of Vice President, Emerging Therapies. In this role Maners will be responsible for the development of new therapeutic applications for the company's Spray Cryotherapy technology.

"Wendelin has an impressive track record of working closely with executive teams and applying a thoughtful, analytical and collaborative approach to building new markets and solidifying current platforms," said Bill Floyd, CEO and president of CSA Medical. "Throughout her career she has also executed over $3 billion in transactions that provided product and therapy diversification to maximize shareholder value. We are thrilled to have her join our team."

Maners brings to CSA Medical more than 18 years of global medical device experience focused on acquisition, licensing and marketing emerging technologies. Most recently she served as Vice President, Strategy and Business Development at Boston Scientific Corporation where she developed and executed acquisition and investment strategies in the Neuromodulation and Electrophysiology markets, as well as new markets for the company. During her tenure at Boston Scientific, Maners' focus also included entering the implantable microelectronics space with the acquisition of Advanced Bionics and leading the due diligence and negotiations for the acquisition of CryoCor, an endocardial cryo ablation technology for atrial fibrillation. From 2000-2003, Ms. Maners worked as an investment banker with Barrington Associates (Wells Fargo Securities). Previously she held marketing positions focused on entering new markets with Boston Scientific's urology and interventional neuroradiology divisions. Maners holds a bachelor of science degree in Business Administration from the University of Southern California Marshall School of Business.

"I believe that CSA Medical's Spray Cryotherapy device has tremendous potential to treat multiple disease states, drastically improve patient outcomes and reduce the cost of healthcare," said Maners. "I look forward to working with my colleagues to realize the fullest potential for this innovative technology."

About CSA Medical

CSA Medical, Inc. develops and manufactures a proprietary therapeutic interventional platform, the Spray Cryotherapy System, comprised of a device, specialty catheters and agent that allows delivery of therapeutic doses of a cryogen to flash freeze and destroy diseased tissue inside the body. The Company is the first to harness the power of extreme cold (-196 C) liquid nitrogen therapeutic energy delivery inside the body. To learn more, please visit www.CSAmedical.com.


'/>"/>
SOURCE CSA Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016 Research and Markets has announced ... Growth and Demand Forecast to 2022" report to their offering. ... , , ... in 2015, and it is expected to grow at a CAGR of ... to witness faster growth during the forecast period, a CAGR of 8.8% ...
(Date:12/2/2016)... Dec. 2, 2016 In the first ever ... from those derived from C. sativa, the Hebrew University ... di Napoli Federico II , the Universita` del Piemonte ... comprehensive, critical, integrated and unified inventory of phytocannabinoids of ... focuses on the remarkable chemical and structural diversity of ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, ... of Pharmaceutical Specialties, Inc. ("PSI").  The combination of ... Georgia -based PSI bring together both company,s clinical ... manufacturers, and payers an industry-leading specialty pharmacy. About ... , , ...
Breaking Medicine Technology:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... today that they have teamed up with The American College of Surgeons (ACS) ... ACS’s Committee on Trauma, the “Bleeding Control Basic” course is a pilot program ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Tasting Event in New York City, with long-time partners The Paul Foundation, on ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... ... December 04, 2016 , ... ... cosmetic surgery can now take advantage of a cosmetic procedure known as ... treatment that reduces the appearance of age spots, fine lines, uneven coloration, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with First 5 ... services to more than 15,900 children 5 years old and younger and treatment services ... over a span of five years to Western University of Health Sciences, UCLA and ...
Breaking Medicine News(10 mins):